These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 8700340)

  • 1. [Short term assessment of anthropometric indices and metabolic parameters in obese subjects treated with acarbose].
    Coli P; Pea E; Lacorte M; Passaglia C; Carrai M
    Minerva Med; 1996 Apr; 87(4):161-70. PubMed ID: 8700340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
    García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
    Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
    Sieradzki J; Soszyński P
    Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in glycaemic status do not predict weight loss in response to hypocaloric diets in obese patients.
    de Luis DA; Aller R; Izaola O; Gonzalez Sagrado M; Conde R
    Clin Nutr; 2006 Feb; 25(1):117-22. PubMed ID: 16278036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
    Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the safety and efficacy of acarbose in diabetes mellitus.
    Yee HS; Fong NT
    Pharmacotherapy; 1996; 16(5):792-805. PubMed ID: 8888075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of acarbose on familiar hypertriglyceridemias.
    Malaguarnera M; Giugno I; Panebianco MP; Pistone G
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):441-5. PubMed ID: 9726698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
    Hasegawa T; Yoneda M; Nakamura K; Ohnishi K; Harada H; Kyouda T; Yoshida Y; Makino I
    J Gastroenterol Hepatol; 1998 Dec; 13(12):1201-6. PubMed ID: 9918426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of acarbose as monotherapy in NIDDM patients.
    Deerochanawong C; Serirat S; Kornthong P
    J Med Assoc Thai; 1996 Feb; 79(2):69-75. PubMed ID: 8868016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
    Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
    Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
    Robertson J; Nelson R; Kass P; Neal L
    Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acarbose reduces blood pressure in sucrose-induced hypertension in rats.
    Madar Z; Melamed EC; Zimlichman R
    Isr J Med Sci; 1997 Mar; 33(3):153-9. PubMed ID: 9313782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
    Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
    Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bofu-tsusho-san, an oriental herbal medicine, in obese Japanese women with impaired glucose tolerance.
    Hioki C; Yoshimoto K; Yoshida T
    Clin Exp Pharmacol Physiol; 2004 Sep; 31(9):614-9. PubMed ID: 15479169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [TNF-alpha and carbohydrate and lipid parameters in overweight and obese children].
    Goral J
    Ann Acad Med Stetin; 2008; 54(2):14-21. PubMed ID: 19374226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
    Clissold SP; Edwards C
    Drugs; 1988 Mar; 35(3):214-43. PubMed ID: 3286212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
    Scheen AJ
    Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic characteristics of glucose intolerance: the critical role of obesity.
    Sainaghi PP; Castello L; Bergamasco L; Carnevale Schianca GP; Bartoli E
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):86-93. PubMed ID: 17972239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
    Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
    Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.